To include your compound in the COVID-19 Resource Center, submit it here.

Bexxar tositumomab: Phase II; BLA under review

CLTR and partner SmithKline Beecham (LSE:SB;SBH, Philadelphia, Penn.) said that in a Phase II trial of Bexxar

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE